期刊文献+

胸腺切除治疗眼肌型重症肌无力的远期疗效及影响因素 被引量:3

Long-term Outcome and Relevant Factors of Thymectomy in Ocular Myasthenia Gravis
下载PDF
导出
摘要 目的:评价胸腺切除治疗眼肌型重症肌无力(OMG)的远期疗效及其影响因素。方法:回顾性分析胸腺切除治疗59例OMG的临床资料,其中采用部分胸骨劈开切口44例,全胸骨劈开切口2例,电视胸腔镜经右胸前外侧径路13例。所有病例均进行随访和疗效评价。结果:全组无手术死亡,术后发生肌无力危象1例;手术有效率1年内89.8%(53/59),1-3年74.0%(37/50),3-5年86.1%(31/36),5-10年88.9%(24/27),10年以上86.7%(13/15);总缓解率37.3%,有效率为86.4%。单因素与多因素分析均显示疗效与性别、年龄、病程、手术径路及病理分型无关(P>0.05)。结论:胸腺切除是OMG的有效治疗方法,切除径路首选电视胸腔镜手术。 Objective: To evaluate the long-term outcome and relevant factors of thymectomy in ocular myasthenia gravis (OMG). Methods: 59 patients with OMG. who accepted thymectomy between October 1978 and August 2003, were studied retrospectively. The operations were performed through variant approaches including 44 partial sternal splits, 2 full sternotomies and 13 video-assisted thoracoscopic thymectomies through anterior lateral approach. And follow-up ranged from 6 to 149 months (mean 69. 8 months) was carried out in all cases. Then the long-term outcome and relevant factors were analyzed. Results: No operative death was found. Myasthenia crisis occurred postoperatively in 1 case. The effective rates were 89.8% (53/59) in 1 year, 74.0% (37/50) in 1-3 years, 86. 1%(31/36) in 3-5 years, 88.9%(24/27) in 5-10 years and 86.7% (13/15) over 10 years, respectively. The total remission rate was 37.3% and effective rate was 86. 4%. There was no correlation between the long-term outcome and sex, age. duration of disease, operative approach, pathological classification of thymus, P>0. 05. Conclusion:Thymectomy for OMG is effective, and video-assisted thoracoscopic surgery is preferred for thymectomy.
出处 《中国临床医学》 北大核心 2005年第3期398-400,共3页 Chinese Journal of Clinical Medicine
关键词 眼肌型重症肌无力 胸腺切除 手术径路 预后 Ocular myasthema gravis Thymectomy Surgical approach Prognosis
  • 引文网络
  • 相关文献

参考文献13

  • 1Wakata N, lguchi H, Sugimoto H,et al. Relapse of ocular symptorns after remission of myasthenia gravis-a comparison of relapsed and complete remission cases[J]. Clinical Neurology and Neurosurgery,2003,105(2), 75-77.
  • 2谭群友,王如文,蒋耀光,赵云平,龚太乾,周景海,马铮,林一丹.胸腺切除治疗儿童重症肌无力43例的远期疗效及影响因素分析[J].重庆医学,2004,33(2):177-178. 被引量:2
  • 3钱升广,郑如恒,王群,乔玉磊.胸腺瘤合并重症肌无力的围手术期处理[J].中国临床医学,2002,9(4):398-398. 被引量:3
  • 4蒋耀光,陈建明,王如文,范士志,廖祥丽.单纯眼肌型重症肌无力胸腺切除的适应证探讨[J].中国胸心血管外科临床杂志,1998,5(1):4-5. 被引量:13
  • 5Busch C, Machens A, Pichlmeier U, et al. Long-term outcome and quality of life after thymectomy for myasthenia gravis[J]. Ann Surg,1996, 224(2): 225-232.
  • 6Roberts PF, Venuta F, Rendina E, et al. Thymectomy in the treatment of ocular myasthenia gravis[J]. J Thorac Cardiova.sc Surg, 2001,122(3) : 562-568.
  • 7崔丽英,汤晓芙,管宇宙,王含,李本红,杜华.单纤维肌电图在眼肌型重症肌无力中的应用(附80例报告)[J].中国神经免疫学和神经病学杂志,2002,9(2):75-78. 被引量:16
  • 8Kupersmith MJ, l.atkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis[J]. ArchNeurol,2003,60(2) : 243-248.
  • 9Monsul NT, Patwa HS, Knorr AM, et al. The effect of prednisone on the progression from ocular to generalized myasthenia gravis[J]. J Neurol Sci, 2004, 217(2) : 131-133.
  • 10Nakamura H, Taniguchi Y, Suzuki Y, et al. Delayed remission after thymectomy for myasthenia gravis of the purely ocular type[J]. J Thorae Cardiovasc Suru, 1996, 112(2) : 371-375.

二级参考文献13

共引文献54

同被引文献22

  • 1李志军,张颖,崔永生.重症肌无力合并胸腺瘤的临床特点[J].中国现代医学杂志,2006,16(7):1055-1057. 被引量:8
  • 2王旭广,杨鲲鹏,寿化山,丁旭青,郭亮.重症肌无力胸腺切除术后发生肌无力危象的危险因素[J].中华胸心血管外科杂志,2006,22(4):268-269. 被引量:15
  • 3谢琰臣,许贤豪,张华,殷剑,刘银红,国红,矫毓娟,孟晓梅,冯凯,王红,许贤豪,张华,殷剑,刘银红,国红,矫毓娟,孟晓梅,冯凯,王红.以大剂量糖皮质激素冲击为主综合治疗重症肌无力的临床观察[J].中华神经科杂志,2006,39(8):511-515. 被引量:28
  • 4张志国,芮军,杨世英,黎新建.重症肌无力27例的外科治疗[J].四川医学,2007,28(4):408-409. 被引量:2
  • 5Newsom-Davis J, Cutter G, Wolfe GI, et al. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann N Y Acad Sci, 2008, 1132: 344-347.
  • 6Mee J, Paine M, Byrne E, et al. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol, 2003, 23: 251-255.
  • 7Kupersmith M J, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol, 2003, 60: 243-248.
  • 8Bhanushali M J, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology, 2008, 71 : 1335-1341.
  • 9Chirapapaisan N, Tanormrod S, Chuenkongkaew W. Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis. Asian Pac J Allergy Immunol, 2007, 25: 13-16.
  • 10Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol, 2005, 89: 1330-1334.

引证文献3

二级引证文献8

;
使用帮助 返回顶部